According to this report, the use of rapid molecular assays has diagnostic value in tuberculosis (TB) identification and detection of drug resistance, although there is not enough evidence to recommend these tools in all populations and situations and they should not replace standard diagnostic methods.
This report sets out the evidence on IGRAs and their use in the diagnosis of latent and active tuberculosis.After reviewing all available evidence, the expert panel concluded that ‘IGRAs should not replace the standard diagnostic methods for diagnosing active TB.’
The ERLTB-Net sub-network of reference laboratories from EU/EEA Member States supports harmonisation of methods and laboratory capacity for tuberculosis diagnosis, antimicrobial susceptibility testing and typing in the EU/EEA.